About Fresenius Kabi Oncology Limited
Data last updated:
Fresenius Kabi Oncology Limited is a public limited company based in New Delhi, Delhi, India, a subsidiary of Fresenius Kabi (Singapore) Pte Ltd. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 18 March 2003 and has been in existence for over 23 years.
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U24231DL2003PLC119441. Its GSTIN is 07AABCD7720L1ZK (Delhi). The company holds 11 GST registrations, of which 4 are active.
The company has an authorised share capital of ₹50 Cr and a paid-up capital of ₹48.04 Cr. It was formerly known as Dabur Pharma Limited. It is led by directors including Arvind Kumar Sharma (Managing Director) and Nikhil Kulshreshtha (Nodal Officer).
Its last annual general meeting (AGM) was held on 20 August 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at B – 310 Som Datt Chambers – I Bhikaji Cama Place, New Delhi, Delhi, India – 110066.
As per the financials filed for FY 2025, the company reported a revenue of ₹848.26 Cr, a growth of 4% compared to the previous year. For the same year it recorded a net profit of ₹75.13 Cr (net margin 8.9%) and EBITDA of ₹162.4 Cr (EBITDA margin 19.1%). Revenue has grown at a compounded annual rate (CAGR) of 6% over three years and 5% over five years.
The company has about 1,165 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Fresenius Kabi Oncology. As per MCA filings, the company has satisfied charges of ₹240.7 Cr on record. Court records list 148 cases involving the company, including 114 filed by the company and 34 filed against it; 13 cases are pending. The company has 6 deals on record (3 market trades, 2 acquisitions, 1 funding round), with disclosed funding of ₹65.48 Cr; the latest was in November 2012. Its 4 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 2 larger and 2 smaller; the largest is Fresenius Kabi India Private Limited with revenue of ₹934 Cr. The company has 4 MSME Form 1 returns on record between 2019 and 2022, listing 35 overdue payments to 19 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website fresenius-kabi-oncology.com.
Company details
CIN history
Fresenius Kabi Oncology has one previous CIN (Corporate Identification Number): L24231DL2003PLC119441. The current CIN is U24231DL2003PLC119441, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24231DL2003PLC119441 | Current |
| L24231DL2003PLC119441 | Previous |
Contact details
Fresenius Kabi Oncology Limited's registered office is in New Delhi, Delhi. Its website is fresenius-kabi-oncology.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Social Media
- Registered AddressB – 310 Som Datt Chambers – I Bhikaji Cama Place, New Delhi, Delhi, India – 110066
- IndustryPharma, Drug Formulation & Development
To see the full contact details of Fresenius Kabi Oncology Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Fresenius Kabi Oncology operates one associated brand: Fresenius Kabi Oncology. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Development and manufacturing of pharmaceutical products for oncology treatments. | fresenius-kabi-oncology.com |
Business activity
The main business activities of Fresenius Kabi Oncology are manufacturing and professional, scientific and technical. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products and scientific research and development. 2 activity segments are registered with the MCA.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | |
| M | Professional, Scientific and Technical | M5 | Scientific research and development |
To see the full business activity and turnover split of Fresenius Kabi Oncology Limited, buy the company report.
Financials of Fresenius Kabi Oncology Limited
FY 2025 filings availableFresenius Kabi Oncology Limited reported revenue of ₹848.26 Cr (up 4% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR)
Revenue has grown at a compounded annual rate (CAGR) of 5% over five years, including 4% growth in the latest year. EBITDA rose 18% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | |||||
| Other Income | |||||
| Total Revenue | |||||
| Cost of Materials Consumed | |||||
| Employee Benefit Expense | |||||
| Finance Costs | |||||
| Depreciation and Amortisation | |||||
| Other Expenses | |||||
| Total Expenses | |||||
| EBITDA | ₹162.4 Cr | ||||
| Profit Before Tax | |||||
| Tax Expense | |||||
| Net Profit (PAT) | ₹75.13 Cr | ||||
| Balance Sheet | |||||
| Share Capital | |||||
| Reserves and Surplus | |||||
| Net Worth (Total Equity) | |||||
| Long-term Borrowings | |||||
| Short-term Borrowings | |||||
| Trade Payables | |||||
| Total Liabilities | |||||
| Fixed Assets | |||||
| Investments | |||||
| Inventories | |||||
| Trade Receivables | |||||
| Cash and Bank Balance | |||||
| Total Assets | |||||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 19.1% | ||||
| Net Profit Margin | 8.9% | ||||
| Return on Equity (ROE) | |||||
| Return on Capital Employed (ROCE) | |||||
| Return on Assets (ROA) | |||||
| Liquidity and Debt | |||||
| Current Ratio | |||||
| Quick Ratio | |||||
| Debt-to-Equity Ratio | |||||
| Interest Coverage Ratio | |||||
| Efficiency and Growth | |||||
| Asset Turnover | |||||
| Receivable Days | |||||
| Payable Days | |||||
| Inventory Days | |||||
| Revenue Growth | |||||
| Net Profit Growth | |||||
To see the full financial statements and ratios of Fresenius Kabi Oncology Limited, buy the company report.
Board of directors of Fresenius Kabi Oncology Limited
Fresenius Kabi Oncology has 5 current directors and 40 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Nikhil Kulshreshtha | Nodal Officer | 19 Aug 2020 | 6 Years 2 Months | Current |
| Maximilian Alexander Bohmer | Director | 29 Aug 2023 | 3 Years 2 Months | Current |
| Arvind Kumar Sharma | Managing Director | 01 Jul 2018 | 8 Years 4 Months | Current |
| Heike Susanne Van Dawen | Director | 04 Jun 2024 | 2 Years 5 Months | Current |
| Eduardo Ricardo Dos Santos Montanha | Additional Director | 15 Sep 2025 | 1 Years 1 Months | Current |
Peer comparison
Fresenius Kabi Oncology Limited is compared with the 4 companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Fresenius Kabi India Private Limited | ₹934 Cr (FY 2025) | 10.0% | Ranjangaon, Maharashtra, India | |||
| Lee Pharma Limited | ₹928.7 Cr (FY 2025) | 2.0% | Hyderabad, Telangana, India | |||
| Fresenius Kabi Oncology Limitedthis company | ₹848.26 Cr (FY 2025) | ₹75.13 Cr | 8.9% | 4.0% | 1,165 | New Delhi, Delhi, India |
| Scott Edil Pharmacia Limited | ₹847.96 Cr (FY 2025) | 7.0% | Chandigarh, India | |||
| Apex Laboratories Private Limited | ₹834.88 Cr (FY 2025) | 7.0% | Chennai, Tamil Nadu, India |
To see the full peer comparison of Fresenius Kabi Oncology Limited, buy the company report.
Auditor
Fresenius Kabi Oncology Limited is audited by VMT & Co. LLP for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| VMT & Co. LLP | FY 2023 | N500048 |
Shareholding
The shareholding of Fresenius Kabi Oncology Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Promoters | |||||
| Domestic institutional investors (DII) | |||||
| Foreign institutional investors (FII) | |||||
| Public | |||||
| Others |
To see the full shareholding pattern of Fresenius Kabi Oncology Limited, buy the company report.
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 29 Sep 2008 | 10125679 | Idbi Bank Limited | ₹19 Cr | Satisfied | |
| 16 Jul 2008 | 10118682 | Punjab National Bank | ₹15 Cr | Satisfied | |
| 29 Sep 2006 | 10024937 | Hsbc Bank Plc | ₹67 Cr | Satisfied | |
| 31 Dec 2003 | 80040257 | Idbi Bank Limited (Lead Bank) | ₹139.7 Cr | Satisfied |
To see the full charge records of Fresenius Kabi Oncology Limited, buy the company report.
Total charge records: 4 View all charges
Deals & funding
Fresenius Kabi Oncology Limited has 6 deals on record (3 market trades, 2 acquisitions, 1 funding round), with disclosed funding of ₹65.48 Cr; the latest was in November 2012.
Deals on record (5 of 6)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Nov 2012 | Market trade | ₹10.83 Cr | Buyer: The Royal Bank Of Scotland Asia Merchant Bank Singapore Lt Seller: Abn Amro Bank Nv |
| Oct 2012 | Market trade | ₹9.02 Cr | Buyer: The Royal Bank Of Scotland Asia Merchant Bank Singapore Lt Seller: Abn Amro Bank Nv |
| Apr 2008 | Acquisition | Undisclosed | Buyer: Fresenius Kabi AG Seller: International Finance Corporation |
| Feb 2007 | Acquisition | ₹167.05 Cr | Buyer: Alembic Limited Seller: Fresenius Kabi Oncology Limited |
| Mar 2006 | Market trade | ₹5.17 Cr | Buyer: an individual Seller: Puran Associates Pvt. Ltd |
To see the full deal history of Fresenius Kabi Oncology Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Fresenius Kabi Oncology Limited has 148 court cases on record: 114 filed by Fresenius Kabi Oncology, 34 filed against it. 13 cases are pending and 135 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| High courts | 116 | 20 | 6 |
| District courts | 24 | 7 | 7 |
| Supreme Court | 8 | 7 | 0 |
Cases on record (5 of 148)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Nadia, West Bengal | Criminal complaint | Filed by the company against Radiant Techno Builders Pvt. Ltd. and Others | Pending |
| District court, New Delhi, Delhi | Court case (Counter Claim) | Filed by the company against SMS Pharmaceuticals Ltd | Pending |
| High Court of Delhi | Appeal | Filed against the company by SMS Pharmaceuticals Limited | Disposed |
| High Court, TAMIL NADU | Civil suit | Filed against the company by Dr.Reddys Laboratories Limited | Disposed |
| Supreme Court | Court case (1100-Arbitration Matters : SLPs challenging Arbitration Matters) | Filed against the company by M/S. Santuka Associates Pvt. Ltd. | Disposed |
To see the full case history of Fresenius Kabi Oncology Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Fresenius Kabi Oncology Limited has 4 MSME Form 1 returns on record between 2019 and 2022, listing 35 overdue payments to 19 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 19)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Spectrochem Pvt Ltd | |||
| Thomas Baker (Chemicals) Private Limited | |||
| Arora Matthey Ltd | |||
| Drugochem Pvt Ltd | |||
| Uni Klinger Limited |
To see the full MSME payment records of Fresenius Kabi Oncology Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
Fresenius Kabi Oncology Limited has a workforce of 1,165 employees on its EPFO records as of Apr 07, 2024, across 3 active EPFO establishments.
GST
Fresenius Kabi Oncology has 11 GST registrations: 4 active and 7 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AABCD7720L1ZK | Delhi | Active | 01 Jul 2017 |
| 02AABCD7720L1ZU | Himachal Pradesh | Active | 01 Jul 2017 |
| 19AABCD7720L1ZF | West Bengal | Active | 01 Jul 2017 |
| 12AABCD7720L1ZT | Arunachal Pradesh | Active | 19 Mar 2018 |
To see the full GST registrations and return filing status of Fresenius Kabi Oncology Limited, buy the company report.
Recent activity
Fresenius Kabi Oncology Limited has 43 board changes on record since 2007: 7 appointments and 36 cessations. The latest: Eduardo Ricardo Dos Santos Montanha was appointed as Additional Director on 15 Sep 2025.
44 earlier events are in the company report.
Frequently asked questions
Fresenius Kabi Oncology is an active public limited company based in New Delhi, Delhi, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 18 March 2003 (23+ years old) and is registered under CIN U24231DL2003PLC119441.
Fresenius Kabi Oncology has 5 current directors:
- Arvind Kumar Sharma - Managing Director
- Maximilian Alexander Bohmer - Director
- Heike Susanne Van Dawen - Director
- Eduardo Ricardo Dos Santos Montanha - Additional Director
- Nikhil Kulshreshtha - Nodal Officer
The latest financial statements of Fresenius Kabi Oncology on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 20 August 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Fresenius Kabi Oncology is 07AABCD7720L1ZK, registered in Delhi. The company has 11 GST registrations in all, of which 4 are active and 7 are cancelled or inactive. Other active GSTINs include 02AABCD7720L1ZU (Himachal Pradesh), 19AABCD7720L1ZF (West Bengal), 12AABCD7720L1ZT (Arunachal Pradesh).
The CIN (Corporate Identification Number) of Fresenius Kabi Oncology is U24231DL2003PLC119441. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Fresenius Kabi Oncology has 148 court cases on record: 114 filed by the company and 34 filed against it. 13 are pending. Most are in the high courts.
Fresenius Kabi Oncology was incorporated on 18 March 2003, making it 23+ years old. It is registered with the Registrar of Companies, Delhi.
Fresenius Kabi Oncology has 6 deals on record (3 market trades, 2 acquisitions, 1 funding round), with disclosed funding of ₹65.48 Cr; the latest was in November 2012.
The peers of Fresenius Kabi Oncology by revenue are Fresenius Kabi India Private Limited, Lee Pharma Limited, Scott Edil Pharmacia Limited, Apex Laboratories Private Limited, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Eduardo Ricardo Dos Santos Montanha was appointed as Additional Director on 15 Sep 2025. Heike Susanne Van Dawen ceased to be Additional Director on 26 Aug 2024. Marc Alexander Mahl ceased to be Additional Director on 26 Aug 2024. Fresenius Kabi Oncology has 43 board changes on record in total.
Fresenius Kabi Oncology has 4 MSME Form 1 returns on record between 2019 and 2022, listing 35 overdue payments to 19 micro and small suppliers. The latest return was filed on 28 Apr 2022.
Fresenius Kabi Oncology can be reached through the website fresenius-kabi-oncology.com. Its registered office is in New Delhi, Delhi, India.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
